3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
6
Terminated
1
Not yet recruiting
1
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Melanoma
40
Carcinoma, Non-Small-Cell Lung
40
Carcinoma, Renal Cell
29
Urinary Bladder Neoplasms
15
Squamous Cell Carcinoma of Head and Neck
15
Lung Neoplasms
15
Colorectal Neoplasms
15
Stomach Neoplasms
13
Pancreatic Neoplasms
13
Neoplasms
13
Neoplasm Metastasis
13
Ovarian Neoplasms
11
Sarcoma
10
Hodgkin Disease
10
Glioblastoma
10
Carcinoma, Transitional Cell
10
Rectal Neoplasms
9
Triple Negative Breast Neoplasms
8
Prostatic Neoplasms
8
Carcinoma, Hepatocellular
8
Small Cell Lung Carcinoma
7
Kidney Neoplasms
7
Esophageal Neoplasms
7
Colonic Neoplasms
7
Breast Neoplasms
7
Head and Neck Neoplasms
6
Skin Neoplasms
5
Lymphoma, Large B-Cell, Diffuse
5
Carcinoma, Neuroendocrine
5
Carcinoma, Merkel Cell
5
Interventions
balstilimab
2
tremelimumab
1
spartalizumab
1
pembrolizumab
1
lenvatinib
1
Standard of Care
1
Pemetrexed
1
Nivolumab
1
Ipilimumab
1
Carboplatin
1
Axitinib
1
130-nm albumin-bound paclitaxel
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Active not recruiting
×
Diabetes Mellitus, Insulin-Dependent, 12
×
Nivolumab
×
Clear all
NCT07000149
2026-03-10
eVOLVE-RCC02
AstraZeneca
Phase 3
Active not recruiting
1,116 enrolled